Piramal Pharma launched Chlorpromazine Hydrochloride in the US last week. The company reported a 14% growth in its complex ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Prioritising US health, Trump has already frozen the supply of HIV and malaria medication aid to endemic countries.

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now producing increasingly personalised and sophisticated therapies, ...

Timothy Eugene Sullivan, the Chief Financial Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.76 billion market ...

The approval is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) of ...

Takeda has announced the appointment of Julie Kim as the successor to Christophe Weber, effective from June 2026.

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where ...